Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more
Market Cap & Net Worth: Mankind Pharma Ltd (MANKIND)
Mankind Pharma Ltd (NSE:MANKIND) has a market capitalization of $9.98 Billion (₹864.70 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #4305 globally and #144 in its home market, demonstrating a -4.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mankind Pharma Ltd's stock price ₹2094.70 by its total outstanding shares 412805072 (412.81 Million).
Mankind Pharma Ltd Market Cap History: 2023 to 2026
Mankind Pharma Ltd's market capitalization history from 2023 to 2026. Data shows growth from $9.45 Billion to $9.98 Billion (14.52% CAGR).
Index Memberships
Mankind Pharma Ltd is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$58.09 Billion | 4.43% | #10 of 20 |
|
NIFTY MIDCAP 100
NIFMDCP100
|
$274.55 Billion | 0.94% | #47 of 100 |
|
NIFTY 200
NIFTY200
|
$1.08 Trillion | 0.24% | #121 of 200 |
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.19% | #135 of 500 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$342.17 Billion | 0.75% | #53 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.48% | #65 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.19% | #135 of 750 |
Weight: Mankind Pharma Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mankind Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mankind Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Mankind Pharma Ltd's market cap is 0.09 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.53x
Mankind Pharma Ltd's market cap is 0.53 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $9.45 Billion | $87.43 Billion | $12.82 Billion | 0.11x | 0.74x |
| 2024 | $13.73 Billion | $103.35 Billion | $19.13 Billion | 0.13x | 0.72x |
| 2025 | $10.47 Billion | $122.07 Billion | $19.91 Billion | 0.09x | 0.53x |
Competitor Companies of MANKIND by Market Capitalization
Companies near Mankind Pharma Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Mankind Pharma Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Mankind Pharma Ltd Historical Marketcap From 2023 to 2026
Between 2023 and today, Mankind Pharma Ltd's market cap moved from $9.45 Billion to $ 9.98 Billion, with a yearly change of 14.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹9.98 Billion | -4.63% |
| 2025 | ₹10.47 Billion | -23.74% |
| 2024 | ₹13.73 Billion | +45.29% |
| 2023 | ₹9.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Mankind Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.98 Billion USD |
| MoneyControl | $9.98 Billion USD |
| MarketWatch | $9.98 Billion USD |
| marketcap.company | $9.98 Billion USD |
| Reuters | $9.98 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.